These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 36998322)

  • 1. Serum Amyloid a Predicts Prognosis and Chemotherapy Efficacy in Patients with Advanced Pancreatic Cancer.
    Ding H; Yang Q; Mao Y; Qin D; Yao Z; Wang R; Qin T; Li S
    J Inflamm Res; 2023; 16():1297-1310. PubMed ID: 36998322
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Baseline and early changes in circulating Serum Amyloid A (SAA) predict survival outcomes in advanced non-small cell lung cancer patients treated with Anti-PD-1/PD-L1 monotherapy.
    He LN; Fu S; Zhang X; Hu Q; Du W; Li H; Chen T; Chen C; Jiang Y; Zhou Y; Lin Z; Yang Y; Huang Y; Zhao H; Fang W; Zhang L; Hong S
    Lung Cancer; 2021 Aug; 158():1-8. PubMed ID: 34087538
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Blood serum amyloid A as potential biomarker of pembrolizumab efficacy for patients affected by advanced non-small cell lung cancer overexpressing PD-L1: results of the exploratory "FoRECATT" study.
    Di Noia V; D'Argento E; Pilotto S; Vita E; Ferrara MG; Damiano P; Ribelli M; Cannella A; Virtuoso A; Fattorossi A; Ceresoli GL; Milella M; Beretta GD; Tortora G; Bria E
    Cancer Immunol Immunother; 2021 Jun; 70(6):1583-1592. PubMed ID: 33231726
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of SOXIRI
    Li X; Huang J; Wang F; Jiang Q; Huang L; Li S; Guo G
    Ther Adv Med Oncol; 2023; 15():17588359231186029. PubMed ID: 37435561
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A systemic inflammation response index (SIRI) correlates with survival and predicts oncological outcome for mFOLFIRINOX therapy in metastatic pancreatic cancer.
    Pacheco-Barcia V; Mondéjar Solís R; France T; Asselah J; Donnay O; Zogopoulos G; Bouganim N; Guo K; Rogado J; Martin E; Alcindor T; Colomer R
    Pancreatology; 2020 Mar; 20(2):254-264. PubMed ID: 31866391
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real World First-Line Treatments and Outcomes of Nab-Paclitaxel Plus Gemcitabine, mFOLFIRINOX and GEMOX in Unresectable Pancreatic Cancer from a Chinese Single Institution.
    Quan Q; Wang Y; Wang F; Zhang D; Chen X; He W; Zhang B; Guo G
    Curr Oncol; 2020 Dec; 28(1):209-219. PubMed ID: 33704188
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neutrophil-to-lymphocyte ratio and carbohydrate antigen 19-9 as prognostic markers for advanced pancreatic cancer patients receiving first-line chemotherapy.
    Shin K; Jung EK; Park SJ; Jeong S; Kim IH; Lee MA
    World J Gastrointest Oncol; 2021 Aug; 13(8):915-928. PubMed ID: 34457195
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic factors in patients with metastatic or recurrent pancreatic cancer treated with first-line nab-paclitaxel plus gemcitabine: implication of inflammation-based scores.
    Hwang I; Kang J; Ip HNN; Jeong JH; Kim KP; Chang HM; Yoo C; Ryoo BY
    Invest New Drugs; 2019 Jun; 37(3):584-590. PubMed ID: 30324344
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sequence Therapy with FOLFIRINOX and Gemcitabine/Nab-Paclitaxel for Patients with Advanced Pancreatic Cancer: A Monocentre Retrospective Cohort Study.
    Queck A; Elango S; Koch C; Walter D; Schmidt J; Trebicka J; Trojan J; Pession U; Finkelmeier F; Waidmann O
    Oncol Res Treat; 2022; 45(3):79-87. PubMed ID: 34875671
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Unresectable pancreatic ductal adenocarcinoma: Role of CT quantitative imaging biomarkers for predicting outcomes of patients treated with chemotherapy.
    Cheng SH; Cheng YJ; Jin ZY; Xue HD
    Eur J Radiol; 2019 Apr; 113():188-197. PubMed ID: 30927946
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of Nab-Paclitaxel-based Second-line Chemotherapy in Metastatic Pancreatic Cancer.
    Dadi N; Stanley M; Shahda S; O'Neil BH; Sehdev A
    Anticancer Res; 2017 Oct; 37(10):5533-5539. PubMed ID: 28982867
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical outcomes of chemotherapy in patients with undifferentiated carcinoma of the pancreas: a retrospective multicenter cohort study.
    Imaoka H; Ikeda M; Maehara K; Umemoto K; Ozaka M; Kobayashi S; Terashima T; Inoue H; Sakaguchi C; Tsuji K; Shioji K; Okamura K; Kawamoto Y; Suzuki R; Shirakawa H; Nagano H; Ueno M; Morizane C; Furuse J
    BMC Cancer; 2020 Oct; 20(1):946. PubMed ID: 33004032
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical characteristics and blood/serum bound prognostic biomarkers in advanced pancreatic cancer treated with gemcitabine and nab-paclitaxel.
    Blomstrand H; Green H; Fredrikson M; Gränsmark E; Björnsson B; Elander NO
    BMC Cancer; 2020 Oct; 20(1):950. PubMed ID: 33008332
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic factors for survival with nab-paclitaxel plus gemcitabine in metastatic pancreatic cancer in real-life practice: the ANICE-PaC study.
    Fernández A; Salgado M; García A; Buxò E; Vera R; Adeva J; Jiménez-Fonseca P; Quintero G; Llorca C; Cañabate M; López LJ; Muñoz A; Ramírez P; González P; López C; Reboredo M; Gallardo E; Sanchez-Cánovas M; Gallego J; Guillén C; Ruiz-Miravet N; Navarro-Pérez V; De la Cámara J; Alés-Díaz I; Pazo-Cid RA; Carmona-Bayonas A
    BMC Cancer; 2018 Nov; 18(1):1185. PubMed ID: 30497432
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical Outcomes of Second-Line Chemotherapy after Progression on Nab-Paclitaxel Plus Gemcitabine in Patients with Metastatic Pancreatic Adenocarcinoma.
    Lee K; Bang K; Yoo C; Hwang I; Jeong JH; Chang HM; Oh D; Song TJ; Park DH; Lee SS; Lee SK; Kim MH; Park JH; Kim KP; Ryoo BY
    Cancer Res Treat; 2020 Jan; 52(1):254-262. PubMed ID: 31291709
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nanoparticle albumin-bound paclitaxel in elder patients with advanced squamous non-small-cell lung cancer: A retrospective study.
    Liu Y; Dong Y; Zhu H; Jing W; Guo H; Yu J
    Cancer Med; 2020 Feb; 9(4):1365-1373. PubMed ID: 31876976
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metronomic chemotherapy of cyclophosphamide plus methotrexate for advanced breast cancer: Real-world data analyses and experience of one center.
    Lu Q; Lee K; Xu F; Xia W; Zheng Q; Hong R; Jiang K; Zhai Q; Li Y; Shi Y; Yuan Z; Wang S
    Cancer Commun (Lond); 2020 May; 40(5):222-233. PubMed ID: 32390331
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early detection of venous thromboembolism after the initiation of chemotherapy predicts a poor prognosis in patients with unresectable metastatic pancreatic cancer who underwent first-line chemotherapy with gemcitabine plus nab-paclitaxel.
    Yamai T; Ikezawa K; Hiraga E; Kawamoto Y; Hirao T; Higashi S; Daiku K; Maeda S; Abe Y; Urabe M; Kai Y; Takada R; Nakabori T; Fukutake N; Uehara H; Fujita M; Ohkawa K
    PLoS One; 2022; 17(3):e0264653. PubMed ID: 35231078
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessing novel prognostic serum biomarkers in advanced pancreatic cancer: the role of CYFRA 21-1, serum amyloid A, haptoglobin, and 25-OH vitamin D3.
    Haas M; Kern C; Kruger S; Michl M; Modest DP; Giessen C; Schulz C; von Einem JC; Ormanns S; Laubender RP; Holdenrieder S; Heinemann V; Boeck S
    Tumour Biol; 2015 Apr; 36(4):2631-40. PubMed ID: 25472579
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic significance of neutrophil lymphocyte ratio and platelet lymphocyte ratio in advanced gastric cancer patients treated with FOLFOX chemotherapy.
    Lee S; Oh SY; Kim SH; Lee JH; Kim MC; Kim KH; Kim HJ
    BMC Cancer; 2013 Jul; 13():350. PubMed ID: 23876227
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.